Tyrosine Unit Converter

Tyrosine Unit Converter

Convert tyrosine between mg/dL and µmol/L, with the age-dependent reference intervals — and why tyrosine is the wrong analyte to screen for tyrosinaemia type I with.

Tyrosine converter

mg/dL ⇄ µmol/L
Multiply mg/dL by 55.19 to get µmol/L. Tyrosine is usually measured on the same plasma amino acid profile as phenylalanine, and the two are read together.
Intervals are strongly age-dependent — the neonatal range is more than twice as wide as the adult one — and differ between laboratories. Confirm the interval printed on your own report before calling a result abnormal.
55µmol/LExample

Tyrosine 1.0 mg/dL, read against the adult reference interval

Formula and conversion factor

µmol/L = mg/dL × 55.1907
mg/dL = µmol/L ÷ 55.1907
55.1907
derived from the molecular weight of L-tyrosine, 181.19 Da. Tyrosine is phenylalanine plus one hydroxyl group, which is why its factor is the smaller of the two
read with phenylalanine
the two move in opposite directions in phenylalanine hydroxylase deficiency, which is what makes the Phe:Tyr ratio more specific than either alone
succinylacetone, not tyrosine
newborn screening for tyrosinaemia type I is done on succinylacetone. Screening on tyrosine alone both misses affected infants and flags large numbers of unaffected ones
age matters
the neonatal interval reaches about 187 µmol/L against an adult upper limit near 90. A value that is unremarkable at three days old is clearly raised at thirty years

Worked example

Tyrosine 1.0 mg/dL, read against the adult reference interval
1.0 × 55.1907 = 55.19 µmol/L, reported as 55 µmol/L
Within the 30–90 µmol/L adult interval used here
The same 55 µmol/L in a three-day-old sits in the middle of a neonatal interval that runs from about 21 to 187 µmol/L — the number has not changed, the interval has
Alongside a phenylalanine of 620 µmol/L this would give a Phe:Tyr ratio of 11.2, well above 3 and consistent with PKU
Alongside a normal phenylalanine it says almost nothing on its own, which is why tyrosine is rarely reported in isolation

Adult reference intervals published for tyrosine

SourceAdult reference interval (µmol/L)Neonatal band
Labcorp31.1 – 118.1 (over 15 years)21.4 – 186.9 (0–30 days)
Mayo Clinic Laboratories36 – 113 (18 years and over)27 – 188 (under 24 months)
The Hospital for Sick Children, Toronto28 – 87 (over 19 years)27 – 187 (0–30 days)
Figure used on this page30 – 9021 – 187 (0–30 days)
Every published lower limit sits close to 30 µmol/L, and the upper limits disagree by more than 30 µmol/L. The neonatal interval is far wider than the adult one in every source, which is the single most important thing to know before calling a newborn's tyrosine raised.

What raises and lowers tyrosine

DirectionCauseWhat separates it
Raised, newbornTransient tyrosinaemia of the newborn — immaturity of 4-hydroxyphenylpyruvate dioxygenase, prematurity, high protein intake, low ascorbateMuch the commonest cause. Resolves spontaneously; succinylacetone is absent
RaisedTyrosinaemia type I (fumarylacetoacetate hydrolase deficiency)Succinylacetone present. Tyrosine may be only modestly raised, or normal early on
RaisedTyrosinaemia type II — oculocutaneous, with corneal erosions and palmoplantar keratosisUsually a markedly raised tyrosine, often above 1,000 µmol/L, without succinylacetone
RaisedLiver disease and acute liver failureRaised alongside methionine and the other aromatic amino acids; the Fischer ratio falls
LowPhenylketonuria, treated or untreatedRead with the phenylalanine — the Phe:Tyr ratio is the comparison that matters
LowOver-restriction on a phenylalanine-free protein substituteA management question for the metabolic service, not a new diagnosis
The most useful line here is the first: in a newborn, a raised tyrosine is far more often transient than inherited. The second is nearly as important — screening programmes moved to succinylacetone precisely because tyrosine is neither sensitive nor specific for tyrosinaemia type I.

Rarely read alone

Tyrosine is a non-essential amino acid, made from phenylalanine by phenylalanine hydroxylase and used to build catecholamines, thyroid hormone and melanin. The conversion is straightforward — 1 mg/dL is 55.19 µmol/L, from a molecular weight of 181.19 Da — but tyrosine is one of the analytes whose number means almost nothing without the company it keeps. It is reported as part of a plasma amino acid profile, and it is read against the phenylalanine measured on the same sample.

That pairing is the whole point in newborn screening. Phenylalanine hydroxylase deficiency raises phenylalanine and lowers tyrosine, because the tyrosine is no longer being made from it. A raised phenylalanine from any other cause — prematurity, parenteral nutrition, liver disease, a sample taken before feeding is established — leaves tyrosine normal or high. The ratio of the two therefore moves further from normal in true PKU than either value does alone, and stays low when the phenylalanine rise is something else. A low tyrosine also has a management meaning of its own in treated PKU, where the protein substitute has to supply it.

The other direction has a different lesson. In a newborn, much the commonest cause of a raised tyrosine is transient tyrosinaemia of the newborn: immaturity of 4-hydroxyphenylpyruvate dioxygenase, compounded by prematurity, a high protein intake and relatively low ascorbate. It resolves without treatment. The inherited tyrosinaemias are rare by comparison, and tyrosinaemia type I — the dangerous one, causing liver failure, renal tubular disease and hepatocellular carcinoma — is not reliably detected by tyrosine at all. Screening programmes moved to succinylacetone because tyrosine both misses affected infants, whose tyrosine can be unremarkable early on, and flags large numbers of unaffected ones.

Age is the last thing to hold in mind. Neonatal reference intervals for tyrosine run to roughly 187 µmol/L against an adult upper limit near 90, so the same measured value can be entirely ordinary at three days old and clearly raised at thirty years. Published adult intervals themselves disagree by more than 30 µmol/L at the upper end. Convert the number, check it against the interval your own laboratory prints for that age, and read it beside the phenylalanine rather than on its own.

Frequently asked questions

How do I convert tyrosine from mg/dL to µmol/L?

Multiply by 55.1907, derived from the molecular weight of tyrosine, 181.19 Da. A tyrosine of 1.0 mg/dL is 55 µmol/L. To go the other way, divide the µmol/L figure by 55.1907.

What is a normal tyrosine level?

Roughly 30–90 µmol/L in an adult on this page, though published adult intervals run from about 28–87 to 36–113 µmol/L. Intervals are strongly age-dependent: the neonatal range reaches about 187 µmol/L, so a newborn value has to be read against a newborn interval.

What does a low tyrosine mean?

Most often phenylketonuria, treated or untreated, because tyrosine is made from phenylalanine and a block in phenylalanine hydroxylase leaves it low. In treated PKU it can also reflect a protein substitute that is not supplying enough. It should be read alongside the phenylalanine, not alone.

Does a raised tyrosine mean tyrosinaemia?

Usually not, especially in a newborn, where transient tyrosinaemia of the newborn is much the commonest cause and resolves on its own. Liver disease raises it too. Tyrosinaemia type I is diagnosed on succinylacetone, which is why newborn screening programmes use that rather than tyrosine.

Why do screening programmes measure succinylacetone instead of tyrosine?

Because tyrosine is neither sensitive nor specific for tyrosinaemia type I. Affected infants can have an unremarkable tyrosine early on, and large numbers of unaffected newborns have a raised one. Succinylacetone is produced only when fumarylacetoacetate hydrolase is deficient, so it identifies the condition directly.

Related calculators

References

  1. Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017;19(12):1380–1395.
  2. Lepage N, McDonald N, Dallaire L, Lambert M. Age-specific distribution of plasma amino acid concentrations in a healthy pediatric population. Clin Chem. 1997;43(12):2397–2402.
  3. van Spronsen FJ, van Wegberg AMJ, Ahring K, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743–756.

Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.